Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.40 |
| ▸ | TET3 | O43151 | 2/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646454 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL969852 | 0.98 | SMN1; SMN2 (0.44) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL27560919 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL23327985 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL11219458 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL28622180 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL7058764 | 0.80 | HCAR2 (0.42) | HCAR2 | |
| SCHEMBL1533802 | 0.80 | HCAR2 (0.42) | HCAR2 | |
| SCHEMBL28786289 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL6863771 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0228862-B1 | STABILIZED HUMAN TISSUE PLASMINOGEN ACTIVATOR COMPOSITIONS | GENENTECH, INC. (US) | 1992-08-12 | — | — | EP | claimed |
| CN-116847831-A | Pharmaceutical composition of amorphous solid dispersion and preparation method thereof | 深圳市药欣生物科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2022-05-17 | — | — | US | disclosed |
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | ANTEIS SA (CH) | 2020-03-26 | — | — | US | disclosed |
| CN-105189531-B | Peptides for skin rejuvenation and methods of use thereof | 安特易斯有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10543195-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2020-01-28 | — | — | US | disclosed |
| EP-2970382-B1 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | ANTEIS SA (CH) | 2019-09-25 | — | — | EP | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | ANTEIS SA (CH) | 2016-09-22 | — | — | US | disclosed |
| US-9375398-B2 | Peptides for skin rejuvenation and methods of using the same | NEOCUTIS S.A. (CH) | 2016-06-28 | — | — | US | disclosed |
| CN-1259991-A | Efferescent compositions and dry effervescent granules | PROCTER & GAMBLE (US) | 2000-07-12 | — | — | CN | disclosed |
| WO-2000020546-A1 | FOAMING SYSTEM AND DETERGENT COMPOSITIONS CONTAINING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-13 | — | — | WO | disclosed |
| EP-0975723-A1 | FOAMING COMPONENT | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0975722-A1 | DETERGENT PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0975724-A1 | EFFERVESCENT COMPOSITIONS AND DRY EFFERVESCENT GRANULES | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999058444-A2 | EFFERVESCENCE COMPONENT | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1998046716-A1 | EFFERVESCENT COMPOSITIONS AND DRY EFFERVESCENT GRANULES | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046714-A1 | DETERGENT PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046715-A1 | FOAMING COMPONENT | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-4423057-A | ANTISECRETORY, ANTICONVULSANT | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TET2 963/4885TET3 1010/4885 |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TET2 963/4885TET3 1010/4885 |
| US-10543195-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TET2 963/4885TET3 1010/4885 |
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TET2 963/4885TET3 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.